Sponsor
Bruce Westerman
Representative · R-AR
Representative · R-AR
The bill expands consumer options, drug access, telehealth, and market‑transparency tools while modernizing HSAs and Medicaid incentives — but it also creates substantial new administrative complexity, tax and coverage tradeoffs, and patient‑safety and provider‑financial risks that could raise costs or reduce protections for some groups.
Millions of taxpayers (including women and small‑business employees) get more flexible, modernized HSAs — higher indexed contribution limits, broader qualified expenses (e.g., menstrual care, direct primary care), limited rollovers from FSAs/HRAs, bankruptcy protection, and a one‑year Saver's Credit election option that can boost refundable tax benefits.
Access and consumer protections for people seeking coverage are strengthened — nationwide issuer acceptance (with limited exceptions), bans on preexisting‑condition exclusions and genetic underwriting, rating‑factor caps, expanded special/enrollment windows, an added low‑cost 'copper' tier, and dependent coverage through age 26 improve affordability options and continuity of coverage for many.
Stronger price‑and‑competition and transparency tools target high health care costs — FTC hospital merger review, Medicare‑style rate authority for high‑market‑power facilities, expanded price/negotiated‑rate transparency, PBM reporting and rebate remittance rules, and protections for pharmacies against retroactive clawbacks aim to lower prices and improve market oversight.
Employers, insurers, providers, states, and plan administrators face large new reporting, verification, certification, and compliance burdens across many program areas (HSAs, exchanges, PBMs, FDA oversight, Medicaid options, telehealth billing), increasing administrative costs that are likely passed on to consumers or taxpayers.
Some provisions risk reducing comprehensive coverage or affordability for particular groups — converting federal plans to fixed HSA deposits, treating employer HSA contributions in ways that limit premium tax credit eligibility, allowing short‑term limited‑duration plans to count as 'health insurance,' and shifts from cost‑sharing caps could raise out‑of‑pocket costs and shrink meaningful coverage
Complex tax changes and new limits (HSA accumulation cap, last‑month rule recapture, dollar caps on IRC §106(h) exclusions, new exchange taxes, and other IRC amendments) create uncertainty, may increase tax bills for some workers, and complicate employer transitions.
Based on analysis of 13 sections of legislative text.
Modernizes HSAs and tax interactions, revises insurer and marketplace rules, alters Medicare/Medicaid payments, strengthens PBM/pharmacy protections, advances drug-competition transparency, and caps noneconomic damages in health lawsuits.
Official title: To address the high costs of health care services, prescription drugs, and health insurance coverage in the United States, and for other purposes.
Introduced May 14, 2026 by Bruce Westerman · Last progress May 14, 2026
Makes broad changes to health policy across tax, private insurance, Medicare, Medicaid, prescription drugs, competition, and liability rules. It modernizes health savings accounts (who may contribute and how limits work), adjusts premium tax credit and insurer enrollment rules, changes Medicare and Medicaid payment formulas and options for states, strengthens drug-approval and competition transparency, imposes PBM/pharmacy protections in Part D, creates FTC funding to investigate health-care anticompetitive behavior, and caps non-economic damages in health-care litigation. The bill affects individuals, employers (including Federal Employee Health Benefits conversion requirements), health insurers and issuers, hospitals, pharmacies and PBMs, state Medicaid programs, and federal agencies (IRS, HHS, CMS, FTC). Many provisions take effect in 2026 or the first taxable year after enactment; others phase in across multiple years and require agency rulemaking and guidance to implement.